Int J Angiol 1996; 5(1): 32-37
DOI: 10.1007/BF02043461
Original Articles

© Georg Thieme Verlag KG Stuttgart · New York

Clinical efficacy of IV prostaglandin E1 and IV pentoxifylline in patients with arterial occlusive disease of fontaine stage IIb: A multicenter, randomized comparative study

Wolfgang Hepp1 , Siegfried von Bary2 , Dejan Corovic3 , Curt Diehm4 , Erich Mühe5 , Gottfried Rudofsky6 , Peter Scheffler7 , Michael Vogelpohl8
  • 1Oskar-Helene-Heim, Freie Universität Berlin, Ulm, Germany
  • 2Krankenhaus Marienhöhe, Würselen, Ulm, Germany
  • 3Klinik Schildautal, Seesen/Harz, Ulm, Germany
  • 4Akademisches Lehrkrankenhaus der Universität Heidelberg, Karlsbad-Langensteinbach, Ulm, Germany
  • 5Kreiskrankenhaus Böblingen, Böblingen, Ulm, Germany
  • 6Universitätsklinikum Essen, Essen, Ulm, Germany
  • 7Universitätsklinikum, Homburg/Saar, Ulm, Germany
  • 8Bundeswehrkrankenhaus, Ulm, Germany
Further Information

Publication History

Publication Date:
23 April 2011 (online)


The IV infusions of both prostaglandin E1 (PGE1) and pentoxifylline showed good efficacy in prolonging the claudication distance and maximum walking range of patients with intermittent claudication, and the Doppler pressures were used as parameters of efficacy. IV PGE1 was significantly superior after 4 weeks' therapy as to both claudication distance and maximum walking range. The ankle pressure indices were significantly elevated in both groups at the end of therapy. The therapeutic effect proved to persist in both groups after a 12 month follow-up, with adverse reactions occurring in two patients treated with PGE1 and in six patients treated with pentoxifylline. The study supports the view that the intravenous infusion of PGE1 is an efficacious and well-tolerated therapy for intermittent claudication.